OncoMed Pharmaceuticals, Inc. clinical trials
Acquired by Mereo BioPharma, Apr 23, 2019 · source ↗
The registry lists 28 studies whose lead sponsor is OncoMed Pharmaceuticals, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 15, 2023.
Before and after it joined Mereo BioPharma
- First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- 28
- First submitted after OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- OncoMed Pharmaceuticals, Inc.28 studies
Something wrong with this grouping? Tell us on the Mereo BioPharma page.
Studies
Recruiting first, then most recently updated. Showing 28 of 28. All Mereo BioPharma studies →
- A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic CancerCompletedNCT01647828Phase 1/2
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT02289898Phase 2
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid TumorsCompletedNCT00744562Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung CancerCompletedNCT02259582Phase 2
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT01189929Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Dose Escalation Study of OMP-59R5 in Subjects With Solid TumorsCompletedNCT01277146Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Dose Escalation Study of OMP-18R5 in Subjects With Solid TumorsCompletedNCT01345201Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid MalignanciesCompletedNCT01703572Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung CancerCompletedNCT01189968Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum TherapyTerminatedNCT01859741Phase 1/2
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant OvarianTerminatedNCT01952249Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal CancerCompletedNCT01189942Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast CancerCompletedNCT01973309Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLCCompletedNCT01957007Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic CancerCompletedNCT02005315Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic CancerCompletedNCT02050178Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube CancerCompletedNCT03030287Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian CancerCompletedNCT02092363Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal CancerCompletedNCT03031691Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Dose Escalation Study of OMP-54F28 in Subjects With Solid TumorsCompletedNCT01608867Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Dose Escalation Study of OMP-52M51 in Subjects With Solid TumorsCompletedNCT01778439Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10CompletedNCT02482441Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic TumorsTerminatedNCT03295942Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Phase 1 Study of OMP-305B83 in Subjects With Solid TumorsCompletedNCT02298387Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular CancerCompletedNCT02069145Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid TumorsCompletedNCT02722954Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of OMP-305B83 in Subjects With Metastatic Colorectal CancerTerminatedNCT03035253Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid TumorsTerminatedNCT03119428Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma